| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.8 |